April 29 (Reuters) - Amicus Therapeutics Inc said its lead drug to treat fat-storage disorder was found effective in patients after 12 months of treatment in a late-stage trial.
The company’s shares jumped about 33 percent in premarket trading. They closed at $1.84 on the Nasdaq on Monday.
The trial evaluated the drug, migalastat, as a form of monotherapy for Fabry disease patients. (Reporting by Natalie Grover in Bangalore; Editing by Don Sebastian)